$Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab$

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab

Mariko Yamashita, Tomo Nishi, Taiji Hasegawa, Nahoko Ogata Department of Ophthalmology, Nara Medical University, Kashihara, Nara, Japan Purpose: To report the effects of aflibercept on eyes with large retinal pigment epithelial detachment (PED) associted with polypoidal choroidal vasculopathy (PCV...

Full description

Bibliographic Details
Main Authors:	Yamashita M, Nishi T, Hasegawa T, Ogata N
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-02-01
Series:	Clinical Ophthalmology
Online Access:	http://www.dovepress.com/response-of-serous-retinal-pigment-epithelial-detachments-to-intravitr-a15703

Similar Items

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
by: Miura M, et al.
Published: (2013-08-01)

Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01)

Comparison of Two-Year Outcome of Photodynamic Therapy in Combination with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2021-01-01)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
by: Kikushima Wataru, et al.
Published: (2020-01-01)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
by: Wataru Kikushima, et al.
Published: (2020-01-01)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
by: James G. Wong, et al.
Published: (2017-04-01)

Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
by: Arakawa A, et al.
Published: (2017-04-01)

Polypoidal choroidal vasculopathy in a case of retinitis pigmentosa, successfully treated with intravitreal aflibercept
by: Nana Takahashi, et al.
Published: (2021-09-01)

Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy.
by: Shotaro Asano, et al.
Published: (2018-01-01)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
by: Sumit Randhir Singh, et al.
Published: (2019-01-01)

One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy
by: Marta Medina-Baena, et al.
Published: (2018-03-01)

Effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in Korea
by: Young Gun Park, et al.
Published: (2015-04-01)

Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
by: Arisa Ito, et al.
Published: (2020-01-01)

One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2019-05-01)

Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
by: Xiaoya Gu, et al.
Published: (2019-07-01)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Ki Won Jin, et al.
Published: (2021-07-01)

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
by: Sakurai M, et al.
Published: (2014-01-01)

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
by: Wataru Matsumiya, et al.
Published: (2011-01-01)

Effect of Epiretinal Membrane Peeling on Intravitreal Aflibercept Therapy Response for Polypoidal Choroidal Vasculopathy: A Case Report
by: Aslı Kırmacı, et al.
Published: (2018-04-01)

AFLIBERCEPT IN TREATMENT OF RESISTANT POLYPOID CHOROIDAL VASCULOPATHY: SHORT-TERM RESULTS
by: E. K. Pedanova, et al.
Published: (2017-12-01)

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy
by: Colin S H Tan, et al.
Published: (2013-01-01)

Clinical implications of pachyvessels in polypoidal choroidal vasculopathy
by: Nobuo Ijuin, et al.
Published: (2020-04-01)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
by: Azuma K, et al.
Published: (2018-08-01)

Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
by: Kunbei Lai, et al.
Published: (2018-06-01)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
by: Maribel Fernández, et al.
Published: (2012-01-01)

Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
by: Aditya Bansal, et al.
Published: (2017-01-01)

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy
by: Jay Kumar Chhablani, et al.
Published: (2013-01-01)

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy
by: Jay Kumar Chhablani, et al.
Published: (2014-01-01)

Early shift from ranibizumab to aflibercept for resistant pigment epitelial detachment in classical choroidal neovascularization
by: Sever Ozkan, et al.
Published: (2017-10-01)

Polypoidal Choroidal Vasculopathy
by: Mirza Metita, et al.
Published: (2018-08-01)

Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results.
by: Mio Matsubara, et al.
Published: (2020-01-01)

Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
by: Vidhi Kathiriya, et al.
Published: (2018-01-01)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
by: Yoshiko Fukuda, et al.
Published: (2021-09-01)

Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
by: Fujii A, et al.
Published: (2014-06-01)

Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy
by: Tien Yin Wong, et al.
Published: (2021-07-01)

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
by: Dogan E, et al.
Published: (2018-08-01)

Characterization of Polypoidal Choroidal Vasculopathy
by: João Henrique Oliveira Saldanha Marques
Published: (2019)

Idiopathic polypoidal choroidal vasculopathy
by: Cekić Sonja, et al.
Published: (2012-01-01)

Polypoidal Choroidal Vasculopathy in Asians
by: Chee Wai Wong, et al.
Published: (2015-04-01)

Title: Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
by: Yoshiko Fukuda, et al.
Published: (2020-07-01)